Compass Pathways jumps on positive Phase 3 COMP006 data for COMP360 in treatment-resistant depression

Compass Pathways plc (CMPS) is up 35.63% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears driven by the company’s announcement that its second pivotal Phase 3 trial (COMP006) for COMP360 met its primary endpoint in treatment-resistant depression, strengthening the overall late-stage package. Investors also seemed to react to the implied regulatory momentum, including plans to engage the FDA on a potential rolling submission.

Details:

The company said COMP006 met its primary endpoint, with two 25 mg doses (administered three weeks apart) showing a statistically significant improvement versus a 1 mg control at Week 6 on the MADRS depression scale.

Compass highlighted a clinically meaningful response signal in COMP006 at Week 6 in the 25 mg arm, alongside rapid symptom improvement observed shortly after dosing and maintained through the primary endpoint window.

The update emphasized tolerability consistent with prior studies, with most treatment-emergent adverse events described as mild-to-moderate and typically resolving within about a day.

Compass disclosed it has requested an FDA meeting to discuss a rolling submission and review and has communicated an expectation to complete an NDA submission in Q4.

Sources:

U.S. SEC

Compass Pathways

Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CMPS Hedge Fund Activity

We have seen 76 institutional investors add shares of $CMPS stock to their portfolio, and 68 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VIVO CAPITAL, LLC removed 3,362,385 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $19,266,466
WOODLINE PARTNERS LP removed 1,755,938 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,061,524
NANTAHALA CAPITAL MANAGEMENT, LLC removed 1,286,637 shares (-74.4%) from their portfolio in Q4 2025, for an estimated $8,877,795
AMERIPRISE FINANCIAL INC added 1,208,784 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,926,332
SIREN, L.L.C. added 1,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6,900,000
MILLENNIUM MANAGEMENT LLC added 974,090 shares (+55.9%) to their portfolio in Q3 2025, for an estimated $5,581,535
TWO SIGMA INVESTMENTS, LP added 960,685 shares (+838.4%) to their portfolio in Q3 2025, for an estimated $5,504,725

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CMPS Price Targets

Multiple analysts have issued price targets for $CMPS recently. We have seen 3 analysts offer price targets for $CMPS in the last 6 months, with a median target of $14.0.

Here are some recent targets:

Leonid Timashev from RBC Capital set a target price of $21.0 on 01/23/2026
Vikram Purohit from Morgan Stanley set a target price of $11.0 on 11/05/2025
Thomas Shrader from BTIG set a target price of $14.0 on 10/13/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.